Day One Biopharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
13 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pimasertib (AS703026) / Day One Biopharma
NCT06208657: Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Recruiting
1/2
82
Canada, RoW
Paxalisib, Irinotecan, Temozolomide
Australian & New Zealand Children's Haematology/Oncology Group, Children's Cancer Institute Australia (CCIA), The Hospital for Sick Children, Medical Research Future Fund, Kazia Therapeutics Limited, C17 Council
Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Recurrent Cancer, Refractory Cancer
12/30
12/35
NCT04789668: Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Completed
1/2
8
US
Bintrafusp Alfa, Anti-PDL1/TGFb Trap MSB0011359C, M7824, MSB0011359C, Pimasertib, AS703026, EMD 1036239, MSC1936369, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Triple-Negative Breast Carcinoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/23
12/23
FIRELIGHT-1, NCT04985604: Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Active, not recruiting
1/2
168
Europe, Canada, US, RoW
Tovorafenib, Pimasertib
Day One Biopharmaceuticals, Inc.
Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation
07/25
12/25
Ojemda (tovorafenib) / Day One Biopharma
LOGGIC, NCT05566795 / 2022-001363-27: DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (/FIREFLY-2)

Recruiting
3
400
Europe, Canada, US, RoW
Tovorafenib, DAY101, Ojemda, Chemotherapeutic Agent, COG-V/C, SIOPe-LGG-V/C, VBL, Carboplatin
Day One Biopharmaceuticals, Inc., SIOPe Brain Tumor Group LOGGIC Consortium
Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
02/26
03/30
2020-003657-30: A Phase 2 Study to Test Effects of Using DAY101 in Children with Brain Cancer

Ongoing
2
60
Europe
DAY101, Tablet
DOT Therapeutics-1 Inc. (Day One), DOT Therapeutics-1 Inc. (Day One)
BRAF-Altered, Recurrent or Progressive Low-Grade Glioma in pediatric patients, Brain tumor in children, Diseases [C] - Cancer [C04]
 
 
FIREFLY 1, NCT04775485: A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Recruiting
2
141
Europe, Canada, US, RoW
Tovorafenib, DAY101
Day One Biopharmaceuticals, Inc., Pacific Pediatric Neuro-Oncology Consortium
Low-grade Glioma, Advanced Solid Tumor
05/27
05/27
NCT05287295: A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Not yet recruiting
2
28
NA
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, FDG PET/CT, Tovorafenib, BIIB-024, DAY 101, DAY-101, DAY101, MLN-2480, MLN2480, pan-RAF Kinase Inhibitor DAY101, TAK-580, TAK580
Children's Oncology Group
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
05/25
05/25
NCT05828069: A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recruiting
2
48
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, FDG-Positron Emission Tomography and Computed Tomography Scan, FDG PET/CT, Lumbar Puncture, LP, Spinal Tap, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Tovorafenib, BIIB 024, BIIB-024, BIIB024, DAY 101, DAY-101, DAY101, MLN 2480, MLN-2480, MLN2480, Ojemda, pan-RAF Kinase Inhibitor DAY101, TAK 580, TAK-580, TAK580
National Cancer Institute (NCI)
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
09/28
09/28
PNOC029, NCT05465174: Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Recruiting
2
57
US
Tovorafenib, DAY101, TAK580, AMG-2112819, BSK1369
Sabine Mueller, MD, PhD, Day One Biopharmaceuticals, Inc.
Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
03/27
03/28
NCT06965114: Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment

Not yet recruiting
1/2
78
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cladribine, 2-CdA, 2CDA, CdA, Cladribina, Leustat, Leustatin, Leustatine, RWJ-26251, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Tovorafenib, BIIB 024, BIIB-024, BIIB024, DAY 101, DAY-101, DAY101, MLN 2480, MLN-2480, MLN2480, Ojemda, pan-RAF Kinase Inhibitor DAY101, TAK 580, TAK-580, TAK580
National Cancer Institute (NCI)
Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia
03/30
03/30
VICTORY, NCT06381570: Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

Recruiting
1
57
Canada
Tovorafenib, Vinblastine
Daniel Morgenstern, The Hospital for Sick Children
Low-grade Glioma
03/27
03/29
PNOC014, NCT03429803: DAY101 In Gliomas and Other Tumors

Active, not recruiting
1
44
US
DAY101, MLN2480, TAK-580
Karen D. Wright, MD, PLGA Fund at Pediatric Brain Tumor Foundation, National Cancer Institute (NCI), Pacific Pediatric Neuro-Oncology Consortium, Team Jack Foundation, Day One Biopharmaceuticals, Inc.
Low-grade Glioma
12/25
12/25
NCT05760586: Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Approved for marketing
N/A
NA
Tovorafenib, DAY101
Day One Biopharmaceuticals, Inc.
Low-grade Glioma
 
 
MSC2015103B / Day One Biopharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pimasertib (AS703026) / Day One Biopharma
NCT06208657: Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Recruiting
1/2
82
Canada, RoW
Paxalisib, Irinotecan, Temozolomide
Australian & New Zealand Children's Haematology/Oncology Group, Children's Cancer Institute Australia (CCIA), The Hospital for Sick Children, Medical Research Future Fund, Kazia Therapeutics Limited, C17 Council
Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Recurrent Cancer, Refractory Cancer
12/30
12/35
NCT04789668: Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Completed
1/2
8
US
Bintrafusp Alfa, Anti-PDL1/TGFb Trap MSB0011359C, M7824, MSB0011359C, Pimasertib, AS703026, EMD 1036239, MSC1936369, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Triple-Negative Breast Carcinoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/23
12/23
FIRELIGHT-1, NCT04985604: Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Active, not recruiting
1/2
168
Europe, Canada, US, RoW
Tovorafenib, Pimasertib
Day One Biopharmaceuticals, Inc.
Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation
07/25
12/25
Ojemda (tovorafenib) / Day One Biopharma
LOGGIC, NCT05566795 / 2022-001363-27: DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (/FIREFLY-2)

Recruiting
3
400
Europe, Canada, US, RoW
Tovorafenib, DAY101, Ojemda, Chemotherapeutic Agent, COG-V/C, SIOPe-LGG-V/C, VBL, Carboplatin
Day One Biopharmaceuticals, Inc., SIOPe Brain Tumor Group LOGGIC Consortium
Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
02/26
03/30
2020-003657-30: A Phase 2 Study to Test Effects of Using DAY101 in Children with Brain Cancer

Ongoing
2
60
Europe
DAY101, Tablet
DOT Therapeutics-1 Inc. (Day One), DOT Therapeutics-1 Inc. (Day One)
BRAF-Altered, Recurrent or Progressive Low-Grade Glioma in pediatric patients, Brain tumor in children, Diseases [C] - Cancer [C04]
 
 
FIREFLY 1, NCT04775485: A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Recruiting
2
141
Europe, Canada, US, RoW
Tovorafenib, DAY101
Day One Biopharmaceuticals, Inc., Pacific Pediatric Neuro-Oncology Consortium
Low-grade Glioma, Advanced Solid Tumor
05/27
05/27
NCT05287295: A Study With DAY101 as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Not yet recruiting
2
28
NA
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, FDG PET/CT, Tovorafenib, BIIB-024, DAY 101, DAY-101, DAY101, MLN-2480, MLN2480, pan-RAF Kinase Inhibitor DAY101, TAK-580, TAK580
Children's Oncology Group
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
05/25
05/25
NCT05828069: A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recruiting
2
48
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography Test, EC, Echocardiography, FDG-Positron Emission Tomography and Computed Tomography Scan, FDG PET/CT, Lumbar Puncture, LP, Spinal Tap, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Tovorafenib, BIIB 024, BIIB-024, BIIB024, DAY 101, DAY-101, DAY101, MLN 2480, MLN-2480, MLN2480, Ojemda, pan-RAF Kinase Inhibitor DAY101, TAK 580, TAK-580, TAK580
National Cancer Institute (NCI)
Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
09/28
09/28
PNOC029, NCT05465174: Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Recruiting
2
57
US
Tovorafenib, DAY101, TAK580, AMG-2112819, BSK1369
Sabine Mueller, MD, PhD, Day One Biopharmaceuticals, Inc.
Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
03/27
03/28
NCT06965114: Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment

Not yet recruiting
1/2
78
NA
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cladribine, 2-CdA, 2CDA, CdA, Cladribina, Leustat, Leustatin, Leustatine, RWJ-26251, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Tovorafenib, BIIB 024, BIIB-024, BIIB024, DAY 101, DAY-101, DAY101, MLN 2480, MLN-2480, MLN2480, Ojemda, pan-RAF Kinase Inhibitor DAY101, TAK 580, TAK-580, TAK580
National Cancer Institute (NCI)
Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia
03/30
03/30
VICTORY, NCT06381570: Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

Recruiting
1
57
Canada
Tovorafenib, Vinblastine
Daniel Morgenstern, The Hospital for Sick Children
Low-grade Glioma
03/27
03/29
PNOC014, NCT03429803: DAY101 In Gliomas and Other Tumors

Active, not recruiting
1
44
US
DAY101, MLN2480, TAK-580
Karen D. Wright, MD, PLGA Fund at Pediatric Brain Tumor Foundation, National Cancer Institute (NCI), Pacific Pediatric Neuro-Oncology Consortium, Team Jack Foundation, Day One Biopharmaceuticals, Inc.
Low-grade Glioma
12/25
12/25
NCT05760586: Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Approved for marketing
N/A
NA
Tovorafenib, DAY101
Day One Biopharmaceuticals, Inc.
Low-grade Glioma
 
 
MSC2015103B / Day One Biopharma
No trials found

Download Options